Glioblastomas also demonstrate higher levels of multiple adenosine receptors (ADORA1/A1R, ADORA3/A3R) compared to all other cancer subtypes, suggesting that gliomas may have particularly active purinergic signaling, and therefore represent an attractive target for anti-CD73 therapy. This evidence concerns the gene ADORA3 and central nervous system cancer.